Illumina Inc. announced on September 3, 2025, the broad launch of Illumina Protein Prep, an assay designed to introduce superior performance for next-generation sequencing (NGS)-based proteomics discovery at scale. This assay, previously available through an early-access program, is now accessible to customers worldwide.
Illumina Protein Prep enables researchers to integrate proteomics into large-scale genomics studies, fostering new insights across cancer, cardiometabolic, and immunologic diseases. The streamlined sample-to-analysis workflow is expected to accelerate drug discovery and development efforts.
This major product launch significantly expands Illumina's multiomics portfolio, offering a comprehensive solution for protein expression profiling. By providing advanced tools for proteomic insights, Illumina aims to unlock deeper understandings of disease mechanisms and facilitate the development of new therapies.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.